Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

GPhA Warns FDA On ANDA Review Transparency

This article was originally published in The Pink Sheet Daily

Executive Summary

User fee negotiations could be 'lengthy and very detailed' unless FDA does 'the right thing' and implements 'effective' communication practices, generic trade group says.


Related Content

Generic User Fee Renewal Talks Faced 'Buyer's Remorse' From GDUFA I
GDUFA Stakeholder Deadline May Come After Negotiations Conclude